Research
Molecular
There is a significant difference in the profile of reporting risk and time-to-onset of GADRs between semaglutide and liraglutide.
Understanding these differences can help tailor obesity treatment to individual patient needs.
StrongSupportsmedium confidence
The thirteen GADRs associated with these two GLP-1RAs showed a significant difference in the profile of reporting risk and time-to-onset.
Why this rating
Based on the analysis of real-world data from a pharmacovigilance database.
Source
Difference in Gastrointestinal Risk Associated with Use of GLP-1 Receptor Agonists: A Real-World Pharmacovigilance Study
Yu Zhou et al. · DOAJ (DOAJ: Directory of Open Access Journals) · 2022
other · n=6222Cited 15×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →